Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Gastroenterology

Monitoring and Long-Term Health

At a Glance

Long-term management of autoimmune gastritis requires regular endoscopy monitoring because the altered stomach lining increases the risk for small growths like Type 1 gNETs. Your doctor will use biopsy staging systems like OLGA to determine your personalized screening schedule.

Once you have stabilized your nutrient levels, the focus of managing Autoimmune Gastritis (AIG) shifts to long-term monitoring. Because the stomach lining has been altered by the immune system, it is considered a precancerous condition [1][2]. While this sounds frightening, the purpose of regular monitoring (surveillance) is to find and treat any changes early, before they become serious [3][4].

The Role of Hypergastrinemia and ECL Cells

The “engine” behind many of the changes in your stomach is a hormone called gastrin [5]. Because your stomach is no longer producing acid, your body produces massive amounts of gastrin to try to stimulate acid production [6].

This chronic hypergastrinemia (high gastrin) acts like a growth hormone for specialized cells in your stomach called enterochromaffin-like (ECL) cells [7][8]. Over time, these cells can go through a stepwise progression [9]:

  1. Linear/Micronodular Hyperplasia: The ECL cells begin to grow in small groups or lines [9].
  2. Dysplasia: The cells begin to look abnormal under a microscope [9].
  3. Type 1 Gastric Neuroendocrine Tumors (gNETs): These are small, usually slow-growing growths that are typically well-differentiated and have a very low risk of spreading [4][10].

Understanding Your Risks

There are two main types of growths that doctors monitor for in AIG patients:

  • Type 1 gNETs: These are the most common growths in AIG. They are driven by high gastrin levels and are often found during routine endoscopies [9][3].
  • Gastric Adenocarcinoma: This is a more traditional form of stomach cancer. While AIG is a risk factor, recent research suggests that the risk of this cancer in AIG patients may be lower than previously thought, especially if the damage is restricted only to the body (corpus) of the stomach [11][12]. The risk increases significantly if you have also had an H. pylori infection [13][14].

Surveillance Guidelines: How Often to Screen?

There is ongoing debate among experts about exactly how often patients should have an endoscopy. Two major sets of guidelines provide different approaches:

  1. MAPS II Guidelines (Europe): These guidelines are generally more proactive, recommending systematic endoscopic surveillance for all patients with severe stomach thinning (atrophy) [15][3].
  2. AGA Guidelines (USA): These guidelines tend to be more conservative. They do not recommend routine screening for every patient, but instead suggest “shared decision-making” between the doctor and patient based on individual risk factors [15].

Risk Stratification

To decide your schedule, doctors use the OLGA or OLGIM staging systems from your biopsy reports [16].

  • Low Risk (Stages I & II): May require less frequent monitoring [17].
  • High Risk (Stages III & IV): Usually involves more frequent endoscopies (often every 3 years) because these stages represent more advanced tissue changes like intestinal metaplasia [17][18][16].

Monitoring is not about waiting for something bad to happen; it is about staying ahead of the disease so you can live a long, healthy life [2].

Growth Type Driver Typical Behavior Management
Type 1 gNET High Gastrin Small, slow-growing Often removed during endoscopy.
Adenocarcinoma Atrophy/Metaplasia Potentially aggressive Frequent surveillance for early detection.
Hyperplasia High Gastrin Precursor to gNETs Monitored via biopsy.

Common questions in this guide

Why is my gastrin level so high with autoimmune gastritis?
Because autoimmune gastritis destroys the cells that make stomach acid, your body overproduces a hormone called gastrin to try and stimulate acid production. This condition, known as hypergastrinemia, acts like a growth hormone for certain stomach cells and can cause small tumors to form over time.
What are Type 1 gastric neuroendocrine tumors (gNETs)?
Type 1 gNETs are the most common growths found in patients with autoimmune gastritis. They are small, slow-growing tumors caused by high gastrin levels. They have a very low risk of spreading and are often simply removed during a routine endoscopy.
What do the OLGA and OLGIM staging systems mean on my biopsy report?
The OLGA and OLGIM staging systems are used by pathologists to score the amount of tissue damage and thinning found in your stomach biopsy. Stages I and II indicate a lower risk, while Stages III and IV indicate a higher risk that usually requires more frequent monitoring.
What is my risk for stomach cancer with autoimmune gastritis?
While autoimmune gastritis is considered a precancerous condition, the risk of traditional stomach cancer (gastric adenocarcinoma) is lower than previously thought for many patients. However, your risk increases significantly if you have a history of an H. pylori infection.
How often should I get an endoscopy for autoimmune gastritis?
Endoscopy frequency depends on your individual risk factors and the specific guidelines your gastroenterologist follows. High-risk patients with advanced tissue changes typically need an endoscopy every three years, while low-risk patients may need less frequent monitoring based on shared decision-making.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my specific OLGA or OLGIM stage, and how does this stage affect the frequency of my endoscopies?
  2. 2.Did my biopsy show any signs of intestinal metaplasia or dysplasia, and if so, how does that change my risk profile?
  3. 3.Do I have evidence of ECL-cell hyperplasia (linear or micronodular), and what does that mean for my risk of neuroendocrine tumors?
  4. 4.Given that I have AIG, do you follow the MAPS II guidelines or the AGA recommendations for my surveillance schedule?
  5. 5.Should we be testing my Chromogranin A levels regularly alongside my gastrin?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

How Often to Get an Endoscopy for Autoimmune Gastritis?Is Autoimmune Gastritis Deadly? Risks & Life ExpectancyWhat is ECL Cell Hyperplasia in Autoimmune Gastritis?How Are H. pylori and Autoimmune Gastritis Connected?Gastric NETs vs Stomach Cancer: What's the Difference?What is the Prognosis for Autoimmune Gastritis?

References

References (18)
  1. 1

    Unraveling the Mysteries of Autoimmune Gastritis.

    Soykan İ, Er RE, Baykara Y, Kalkan C

    The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology 2024; (36(3)):135-144 doi:10.5152/tjg.2024.24563.

    PMID: 39632655
  2. 2

    Occurrence and characteristics of endoscopic gastric polyps in patients with autoimmune gastritis (AGAPE study): A multicentric cross-sectional study.

    Massironi S, Gallo C, Lahner E, et al.

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2025; (57(1)):198-205 doi:10.1016/j.dld.2024.07.024.

    PMID: 39112216
  3. 3

    Autoimmune Atrophic Gastritis: A Clinical Review.

    Castellana C, Eusebi LH, Dajti E, et al.

    Cancers 2024; (16(7)) doi:10.3390/cancers16071310.

    PMID: 38610988
  4. 4

    Histopathologic Progression of Autoimmune Atrophic Gastritis: A Retrospective Review of 180 Specimens From 32 Patients.

    Wang X, Jiao J, Huh WJ, Zhang X

    Archives of pathology & laboratory medicine 2025; (150(1)):81-87 doi:10.5858/arpa.2025-0030-OA.

    PMID: 40509896
  5. 5

    Prevalence and predictors of colonoscopic findings in patients with autoimmune gastritis.

    Asfuroglu Kalkan E, Kalkan C, Gumussoy M, et al.

    Journal of investigative medicine : the official publication of the American Federation for Clinical Research 2022; (70(1)):73-78 doi:10.1136/jim-2021-001911.

    PMID: 34341100
  6. 6

    Relevance of pepsinogen, gastrin, and endoscopic atrophy in the diagnosis of autoimmune gastritis.

    Kishikawa H, Nakamura K, Ojiro K, et al.

    Scientific reports 2022; (12(1)):4202 doi:10.1038/s41598-022-07947-1.

    PMID: 35273265
  7. 7

    Correct Identification of Cell of Origin May Explain Many Aspects of Cancer: The Role of Neuroendocrine Cells as Exemplified from the Stomach.

    Waldum H, Mjønes PG

    International journal of molecular sciences 2020; (21(16)) doi:10.3390/ijms21165751.

    PMID: 32796591
  8. 8

    Hypergastrinemia Expands Gastric ECL Cells Through CCK2R+ Progenitor Cells via ERK Activation.

    Sheng W, Malagola E, Nienhüser H, et al.

    Cellular and molecular gastroenterology and hepatology 2020; (10(2)):434-449.e1 doi:10.1016/j.jcmgh.2020.04.008.

    PMID: 32330731
  9. 9

    Unmasking the high-risk phenotype in autoimmune gastritis: A pathologist's roadmap for the clinician.

    Wang CL, Zeng M, Luo Y

    World journal of gastroenterology 2025; (31(48)):115244 doi:10.3748/wjg.v31.i48.115244.

    PMID: 41480315
  10. 10

    Endoscopic features and clinical importance of autoimmune gastritis.

    Kamada T, Maruyama Y, Monobe Y, Haruma K

    Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society 2022; (34(4)):700-713 doi:10.1111/den.14175.

    PMID: 34674318
  11. 11

    Autoimmune gastritis may be less susceptible to cancer development than Helicobacter pylori-related gastritis based on histological analysis.

    Arai J, Niikura R, Hayakawa Y, et al.

    Gut 2024; (73(6)):1037-1038 doi:10.1136/gutjnl-2023-330052.

    PMID: 37197906
  12. 12

    Long-Term Natural History of Autoimmune Gastritis: Results From a Prospective Monocentric Series.

    Miceli E, Lenti MV, Gentile A, et al.

    The American journal of gastroenterology 2024; (119(5)):837-845 doi:10.14309/ajg.0000000000002619.

    PMID: 38050966
  13. 13

    Autoimmune Gastritis in Korean Patients with Gastric Tumors: Clinicopathologic Correlations and Diagnostic Histological Features.

    Ahn S, Kim TS, Kushima R, et al.

    Gut and liver 2025; (19(2)):177-188 doi:10.5009/gnl240223.

    PMID: 39506312
  14. 14

    Endogenous Glucocorticoids Moderate the Gastric Inflammatory Response to Helicobacter Infection and Protect from Autoimmunity.

    Druffner SR, Duncan BC, Morris MT, et al.

    Cellular and molecular gastroenterology and hepatology 2026; (20(4)):101699 doi:10.1016/j.jcmgh.2025.101699.

    PMID: 41453637
  15. 15

    Recent Guidelines on the Management of Patients with Gastric Atrophy: Common Points and Controversies.

    Matysiak-Budnik T, Camargo MC, Piazuelo MB, Leja M

    Digestive diseases and sciences 2020; (65(7)):1899-1903 doi:10.1007/s10620-020-06272-9.

    PMID: 32356261
  16. 16

    Risk factors for gastric cancer in patients with Lynch syndrome.

    Ortigão R, Brito M, Pinto C, et al.

    European journal of gastroenterology & hepatology 2022; (34(9)):912-918 doi:10.1097/MEG.0000000000002405.

    PMID: 35830349
  17. 17

    Gastritis staging as a clinical priority.

    Mescoli C, Gallo Lopez A, Taxa Rojas L, et al.

    European journal of gastroenterology & hepatology 2018; (30(2)):125-129 doi:10.1097/MEG.0000000000001015.

    PMID: 29215433
  18. 18

    Comparison of operative link for gastritis assessment, operative link on gastric intestinal metaplasia assessment, and TAIM stagings among men with atrophic gastritis.

    Nieminen AA, Kontto J, Puolakkainen P, et al.

    World journal of gastroenterology 2020; (26(24)):3447-3457 doi:10.3748/wjg.v26.i24.3447.

    PMID: 32655268

This page provides educational information about long-term monitoring for autoimmune gastritis. Always consult your gastroenterologist to determine the right endoscopy surveillance schedule for your specific risk factors.

Get notified when new evidence is published on autoimmune gastritis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.